Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 23

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 23
---
 risks, and it shall ensure that Company management provides an annual Cybersecurity Risk update to the Board of Directors; • reviewing with management and the independent auditors our accounting policies, including discussing with the independent auditors any changes in our critical accounting principles; • discussing with management its processes for complying with certification requirements under the Sarbanes-Oxley Act; • discussing with the independent auditors any material correcting adjustments identified by the independent auditors; • determining the engagement of the independent auditors, and approving the retention of the independent auditors to perform any proposed permissible non-audit services; • reviewing the scope of the annual audit with the independent auditors and approving the audit fee; • evaluating the independent auditors’ qualifications, independence and performance; • establish hiring policies for employees or former employees of the independent auditors that meet SEC regulations and applicable Nasdaq listing standards; • making recommendations regarding the appointment and replacement of the head of the Company’s internal audit department; 13 • reviewing and approving the internal audit department’s charter, which sets forth the internal audit department’s role, the overall scope of the internal audit plan, and the internal audit department’s budget and resources; • meeting periodically with the head of the Company’s internal audit department to review the scope and results of the internal audit program, discuss any matters warranting the Audit Committee’s attention; • reporting to and reviewing with the Board of Directors the performance of the internal audit department; • review and approve all related-party transactions required to be disclosed pursuant to Item 404 of Regulation S-K; • reviewing and recommending to the Board of Directors whether the Company’s audited financial statements should be included in the Company’s Annual Report on Form 10-K; • preparing a written report to be included in the Company’s annual proxy statement for each Annual Meeting of Stockholders; • reviewing with the independent auditors any material communication between the independent auditor and management; • reviewing, updating and approving a code of conduct and ethics for senior financial officers and certain other employees and agents of the Company; • establishing procedures for the review and treatment of complaints received regarding accounting, internal accounting control or auditing matters; • annually reviewing the Audit Committee’s performance; and • periodically reviewing the Audit Committee charter. Compensation Committee The current members of our Compensation Committee are Dr. Gemayel, who is the Chair of the committee, Mr. Newhall and Mr. Hudson. Each of the members of our Compensation Committee are independent under the applicable rules and regulations of the SEC, The Nasdaq Stock Market and the Internal Revenue Service